Merck gets positive EU opinion to expand Enflonsia use for young children
MRK•Merck received a positive EU committee opinion to expand Enflonsia’s authorization to children up to 24 months old who remain vulnerable to severe RSV disease through their second RSV season; a final EU Commission decision is expected within two months.
1. EU committee opinion
The EU Committee for Medicinal Products for Human Use issued a positive opinion on expanding Enflonsia’s marketing authorization to include children up to 24 months old who remain vulnerable to severe RSV disease through their second RSV season. Merck said a final European Commission decision is expected within two months.
